Cargando…
Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study
PURPOSE: Esophageal squamous cell carcinoma is associated with high morbidity and mortality rate for which radiotherapy is the main treatment modality. Niraparib, a Poly (ADP-ribose) polymerase 1 inhibitors (PARPi) was previously reported to confer radiosensitivity in different malignancies includin...
Autores principales: | Cui, Yuzhong, Huang, Wei, Du, Feng, Yin, Xiaoyang, Feng, Lei, Li, Baosheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283188/ https://www.ncbi.nlm.nih.gov/pubmed/35364771 http://dx.doi.org/10.1007/s12094-022-02818-7 |
Ejemplares similares
-
Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study
por: Cui, Yuzhong, et al.
Publicado: (2022) -
Treatment of Alcohols with Tosyl Chloride Does Not always Lead to the Formation of Tosylates
por: Ding, Rui, et al.
Publicado: (2011) -
Niraparib for ovarian cancer
Publicado: (2021) -
PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
por: Jonuscheit, Stephanie, et al.
Publicado: (2021) -
SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis
por: Feng, Lei, et al.
Publicado: (2021)